SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sotera Health Company – SHC

Sep 23rd, 2022 21:51 EST

New York, New York--(Newsfile Corp. - September 23, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sotera Health Company (""Sotera" or the "Company") (NASDAQ: SHC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Sotera and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On September 19, 2022, news outlets reported that a jury found Sotera's Sterigenics business unit liable for a role in causing a woman's breast cancer and awarded the plaintiff $363 million. The lawsuit specifically alleged that carcinogenic emissions from a Sterigenics plant near the plaintiff's home caused her cancer.

On this news, Sotera's stock price fell $4.90 per share, or 33.27%, to close at $9.83 per share on September 19, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLP[email protected]888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/138346

SHARE

You must be logged in to post a comment.

Related Recent Publications

You must be logged in to post a comment.

Email newsletter

Receive the latest stock news and signals